Todos os posts

Estudo randomizado | Somapacitam semanal é não inferior ao hormônio de crescimento (GH) diário em crianças com deficiência de GH.

8 Set, 2022 | 13:43h

Weekly Somapacitan is Effective and Well Tolerated in Children with GH Deficiency: The Randomized Phase 3 REAL4 Trial – The Journal of Clinical Endocrinology & Metabolism

Estudo de braço único fase 2 | Galunisertibe com quimioterapia neoadjuvante em pacientes com câncer retal localmente avançado.

8 Set, 2022 | 13:42h

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentários:

Addition of Galunisertib to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer – The ASCO Post

Improved Complete Response Rate Observed With Galunisertib Plus Neoadjuvant CRT in Advanced Rectal Cancer – Cancer Network

Estudo randomizado fase 2 | Segurança, tolerabilidade e eficácia da pirfenidona em pacientes com doença pulmonar intersticial associada a artrite reumatoide.

8 Set, 2022 | 13:41h

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Respiratory Medicine

Comentário no Twitter

NEW Research—Pirfenidone slowed the rate of decline of FVC over time in patients with RA-ILD*

Being presented at #ERSCongress, ALERT 3 session, Sept 5 from 13:15 BST

From Joshua Solomon & colleagues https://t.co/Nu8wECECdD

*(please check study limitations) pic.twitter.com/IuRxLDZGd9

— The Lancet Respiratory Medicine (@LancetRespirMed) September 5, 2022

Revisão | Complicações cardiovasculares dos imunoterápicos para câncer.

8 Set, 2022 | 13:40h

Cardiovascular complications of immune checkpoint inhibitors for cancer – European Heart Journal

Conteúdos relacionados:

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program – Journal of Clinical Oncology

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment – Journal of the American Heart Association

Cardiotoxicity of immune checkpoint inhibitors – ESMO Open

Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology – Journal of the Formosan Medical Association

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – JACC: CardioOncology

Comentário no Twitter

Must read state-of-the-art review: Cardiovascular complications of immune checkpoint inhibitors for cancer https://t.co/0lr7g6s8g0
#EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes pic.twitter.com/jORaTzP7GD

— European Society of Cardiology Journals (@ESC_Journals) September 5, 2022